Furthermore, higher sPD-L1 is reported to be associated with shorter overall survival in breast cancer patients after trastuzumab treatment [8], indicating that PD-L1 may ablate the antitumor effect of trastuzumab and T-DM1 in breast cancer. Here, CD274 is linked to breast carcinoma.